Fennec Pharmaceuticals Inc.
TSX:FRX.TO · Toronto Stock Exchange
-$0.22 today
Vol 0.00M · Avg 0.00M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-27.8%
avg 45.2%
ROIC
-10.7%
avg -84.1%
ROA
-13.9%
avg -53.6%
Analysis
ROIC is currently the strongest return metric at -10.7% versus its period average of -84.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jeffrey S. Hackman | Chief Executive Officer & Director | $882,829.00 | — | 63 | — | — |
Robert C. Andrade | Chief Financial Officer | $771,766.00 | — | 51 | — | — |
Pierre S. Sayad | Chief Medical Officer | $648,085.00 | — | — | — | — |
Mark Gowland | Controller | — | — | — | — | — |
Terry Evans | Chief Commercial Officer | — | — | — | — | — |
Christiana Cioffi | Chief Strategy Officer | — | — | — | — | — |
Lei Fang | President of Pharstat Inc | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
NervGen Pharma Corp.
NGEN.V
$407.94M
Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO
$320.56M
Medical Facilities Corporation
TSX:DR.TO
$315.03M
High Tide Inc.
HITI.V
$289.97M
Profound Medical Corp.
TSX:PRN.TO
$285.95M
TerrAscend Corp.
TSX:TSND.TO
$283.25M
Canopy Growth Corporation
TSX:WEED.TO
$245.35M
OrganiGram Holdings Inc.
TSX:OGI.TO
$191.06M
Cybin Inc.
CYBN.NE
$154.92M
Helix BioPharma Corp.
TSX:HBP.TO
$108.46M
Who manages FRX.TO?
Fennec Pharmaceuticals Inc. (FRX.TO) lists 7 active executives. The top listed executive is Pierre S. Sayad, Chief Medical Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.